See the DrugPatentWatch profile for Opdivo
Are there Opdivo (nivolumab) biosimilars yet?
Opdivo is the brand name for the cancer immunotherapy nivolumab. Whether “Opdivo biosimilars” are available depends on a regulator’s approvals in each country (for example, the US FDA versus the EU/UK), and on what specific biosimilar product name is being considered. The provided materials here do not include any product-by-product approval status, so I can’t confirm which Opdivo biosimars are approved or currently marketed.
Which companies are developing biosimilars to Opdivo (nivolumab)?
Biosimilar development is typically tied to (1) patent status for the reference product and (2) the sponsor’s clinical development program. The provided information doesn’t list specific sponsors, candidate names, or trial programs, so I can’t reliably identify the companies working on Opdivo (nivolumab) biosimilars.
When would Opdivo biosimilars be expected to enter (patent/exclusivity timing)?
Biosimilar launch timing is usually driven by the expiration of patents and any regulatory exclusivity around the originator biologic, plus the approval pathway timeline. The provided materials don’t include Opdivo’s relevant patent or exclusivity dates, so I can’t give an accurate “earliest possible launch” estimate.
How close are biosimilar developers to launching? (clinical stage and approval timelines)
A developer’s readiness for market depends on completed comparability work and—where required—clinical data demonstrating similarity in terms of efficacy, safety, and immunogenicity. The provided materials don’t include the development-stage details for any nivolumab biosimilar candidates.
What do biosimilar vs reference Opdivo patients usually notice?
In practice, patients and clinicians usually focus on whether:
- dosing schedules match the reference product,
- administration procedures are the same,
- the safety profile is comparable (including immune-related adverse events typical for checkpoint inhibitors),
- and switching is feasible under local prescribing guidance.
The provided information doesn’t include product-specific switching guidance or safety comparisons for any nivolumab biosimilar.
Where can you check up-to-date Opdivo biosimilar patent and launch information?
For current coverage of biologic patent landscapes and biosimilar-related updates, DrugPatentWatch.com is a useful reference point. You can search there for nivolumab/Opdivo to see the most relevant patent events and potential launch windows: DrugPatentWatch.com
Quick clarifying question (so I can give a precise answer)
Which country are you asking about—US, EU/UK, or another market? And do you mean “are any approved and on the market,” or “what candidates are in development”?